[1] Mishra A, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol, 2015, 35:221-235.
[2] Haga Y, Kanda T, Sasaki R, et al. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J Gastroenterol, 2015, 21:12989-12995.
[3] Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis, 2012, 25:10-16.
[4] Yao S, Zhang J, Chen H, et al. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem, 2013, 61:639-648.
[5] Ba MC, Long H, Tang YQ, et al. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review. Int J Clin Exp Pathol, 2012, 5:874-881.
[6] Wei HS, Kang YF, Hao XH, et al. Serum GP73 were increased in patients with fatty liver disease. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 2013, 27: 244-250.
[7] Xu Z, Liu L, Pan X, et al. Serum Golgi Protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease. Medicine, 2015, 94:659-668.
[8] Qiao Y, Chen J, Li X,et al. Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin Biochem, 2014, 47:216-222.
[9] Liu Y, Zou Z, Zhu B, et al. CXCL10 decreases GP73 expression in hepatoma cells at the early stage of hepatitis C virus (HCV) infection. Int J Mol Sci, 2013, 14:24230-24241. |
